BHV-8000

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameBHV-8000
Drug Alias NameTLL-041TLL041
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase 2Tyrosine-protein kinase JAK1
Therapy Area/IndicationsAmyotrophic Lateral SclerosisAlzheimer DiseaseParkinson Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Highlightll Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBiohaven LtdBiohaven Therapeutics LtdRecipharm Pharmaservices Pvi Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisAlzheimer DiseaseParkinson Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A